Table 2.

Best overall response (per RECIST 1.1, based on investigator assessment)

Response	N=156
Best overall response, n (%)
Complete response	3 (1.9)
Partial response	28 (17.9)
Stable disease	68 (43.6)
Progressive disease	40 (25.6)
Not evaluable*	17 (10.9)
ORR (95% CI), %	19.9 (13.9 to 27.0)
Disease control rate, n (%)	99 (63.4)

*Includes patients with no post-baseline assessment (n=9); stable disease of insufficient duration (<6 weeks without further assessment available; n=4); new therapy started before first post-baseline assessment (n=2); non-evaluable assessments (n=1); or non-evaluable with progressive disease occurring >12 weeks after study assessment (n=1).

ORR, objective response rate; RECIST, Response Evaluation Criteria in Solid Tumors.